Edap Tms (NASDAQ:EDAP) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Edap Tms S.A. (NASDAQ:EDAP) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.59 and traded as high as $4.47. Edap Tms shares last traded at $4.32, with a volume of 55,873 shares.

Analysts Set New Price Targets

Several equities research analysts recently commented on EDAP shares. HC Wainwright lowered their price target on Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Wall Street Zen cut shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Edap Tms Trading Up 2.9%

The company has a fifty day simple moving average of $3.74 and a two-hundred day simple moving average of $3.59. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The company has a market capitalization of $161.91 million, a P/E ratio of -5.33 and a beta of -0.10.

Edap Tms (NASDAQ:EDAP) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $20.48 million for the quarter, compared to the consensus estimate of $19.46 million. Edap Tms had a negative return on equity of 137.61% and a negative net margin of 41.47%. On average, analysts forecast that Edap Tms S.A. will post -0.82 earnings per share for the current fiscal year.

Insider Transactions at Edap Tms

In related news, Director Joshua Levine bought 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $4.22 per share, with a total value of $42,200.00. Following the completion of the transaction, the director directly owned 35,000 shares of the company’s stock, valued at $147,700. This trade represents a 40.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.10% of the stock is owned by insiders.

Institutional Trading of Edap Tms

A number of institutional investors and hedge funds have recently modified their holdings of EDAP. Financial Planning Navigators CORP acquired a new position in Edap Tms in the 4th quarter valued at $33,000. SmartHarvest Portfolios LLC acquired a new position in Edap Tms during the 1st quarter worth $38,000. Lido Advisors LLC acquired a new position in Edap Tms during the 1st quarter worth $40,000. Kovack Advisors Inc. bought a new stake in Edap Tms during the fourth quarter valued at about $53,000. Finally, Leonteq Securities AG bought a new stake in Edap Tms during the fourth quarter valued at about $313,000. 62.74% of the stock is currently owned by institutional investors and hedge funds.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.